For example, compounds that selectively or non-selectively inhibit cholinesterase may help manage AD symptoms based on the “cholinergic theory.” MTDLs based on tacrine, a classical pharmacophore that inhibits both AChE and BuChE at a micro-molar scale, led to the success of memoquin and ferulic acid-memoquin hybrids, which can inhibit both AChE- and self-induced Aβ aggregation [73]. The gene discussed is ACHE; the disease is Alzheimer disease.